No. |
DrugBank |
Drug (Description in trials) [Number of descriptions] |
KEGG DRUG * | KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 | Botulinum toxin type A | [3] Botulinum toxin type a; Botulinum toxin type a (nabota®) injection into the gastrocnemius muscle; Clostridium botulinum toxin type a; | D00783 |
[1] SNAP25 |
[2] Insulin secretion, Synaptic vesicle cycle |
[13] 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226 |
2 | Creatine | [4] Creatine; Creatine monohydrate; Creatine-13c; Pyruvate, creatine, niacinamide; | - |
- |
- |
[12] 1, 2, 5, 6, 8, 13, 46, 49, 50, 113, 156, 201 |
3 | Davunetide | [2] Davunetide; Davunetide (al-108, nap); | D09401 |
- |
- |
[3] 5, 7, 127 |
4 | Donepezil | [4] Donepezil; Donepezil hci (drug); Donepezil hydrochloride; Donepezil sandoz; | D00670 D07869 |
[1] ACHE |
[2] Cholinergic synapse, Glycerophospholipid metabolism |
[9] 5, 6, 13, 46, 78, 124, 127, 156, 206 |
5 | Droxidopa | [1] Droxidopa; | D01277 |
[9] ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
[13] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[3] 5, 6, 17 |
6 | Flortaucipir F-18 | - | - |
- |
- |
[3] 5, 7, 127 |
7 | Flutemetamol | [2] Flutemetamol; Vizamyl (flutemetamol(f-18)); | - |
- |
- |
[5] 5, 6, 7, 17, 127 |
8 | Hydrogen | [2] Hydrogen; Tch346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt); | - |
- |
- |
[5] 5, 6, 17, 97, 226 |
9 | Ioflupane I-123 | [1] Ioflupane i 123; | D10014 |
- |
- |
[3] 2, 5, 6 |
10 | Isoxaflutole | - | - |
- |
- |
[8] 5, 6, 13, 18, 81, 113, 149, 299 |
11 | L-Leucine | [1] L-leucine; | D00030 |
- |
- |
[7] 5, 6, 7, 127, 283, 284, 299 |
12 | Levocarnitine | [4] Levocarnitine; Levocarnitine propyl hydrochloride; Valproate, levocarnitine; Valproic acid and levocarnitine; | D02030 D02176 D04713 |
- |
- |
[10] 3, 5, 13, 53, 58, 96, 97, 265, 298, 316 |
13 | Lipoic Acid | [8] Alpha lipoic acid; Alpha-lipoic acid; Alpha-lipoic acid and l-acetyl carnitine; Lipoic acid; Lipoic acid (la) with fish oil and la without fish oil; Lipoic acid and omega-3 fatty acids; Oral lipoic acid (la); R lipoic acid; | D00048 D00086 |
- |
- |
[5] 2, 5, 13, 14, 20 |
14 | Lithium carbonate | [1] Lithium carbonate; | D00801 |
- |
- |
[8] 2, 5, 7, 8, 13, 17, 19, 127 |
15 | Lithium citrate | - | D04749 |
- |
- |
[4] 2, 5, 7, 8 |
16 | Masitinib | [10] Masitinib; Masitinib (3.0); Masitinib (4.5); Masitinib (6.0); Masitinib (ab1010); Masitinib 100mg; Masitinib 200mg; Masitinib 3 mg; Masitinib 6.0 mg; Masitinib mesylate; | D10229 |
[1] KIT |
[11] Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
[6] 2, 5, 6, 13, 46, 96 |
17 | Nicotinamide | [2] Nicotinamide; Nicotinamide riboside; | D00036 |
- |
- |
[8] 5, 6, 13, 46, 49, 53, 67, 162 |
18 | Nitrogen | [1] Nitrogen; | D00083 |
- |
- |
[5] 5, 6, 17, 211, 299 |
19 | Oxygen | [9] Continuous oxygen; Helium / oxygen mixed gas inhalation therapy; Medical air vs oxygen; Medical grade oxygen; Nitric oxide plus oxygen; Oxygen; Oxygen 40 %; Oxygen supplementation; Perfluorinated gas/oxygen mixture; | D00003 |
- |
- |
[18] 5, 6, 17, 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 211, 226, 299, 330 |
20 | Raclopride | [2] 11c-raclopride; Raclopride; | - |
- |
- |
[4] 5, 6, 7, 17 |
21 | Rasagiline | [16] 1.0 mg rasagiline mesylate; Group r rasagiline; Group r+ad rasagiline + antidepressant; P2b001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),; P2b001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),; Rasagiline; Rasagiline 1 mg capsule; Rasagiline 1mg tablet; Rasagiline 2 mg tablet; Rasagiline mesilate; Rasagiline mesylate; Rasagiline mesylate 1.0 mg; Rasagiline mesylate plus mirapex; Rasagiline mesylate with levodopa; Rasagiline mesylate with requip; Rasagiline tablets; | D02562 D08469 D10829 |
[1] MAOB |
[13] Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
[4] 2, 5, 6, 17 |
22 | Riluzole | [5] Riluzole; Riluzole 50 mg; Riluzole 50 mg (part b); Riluzole oral soluble film; Riluzole oral soluble film (rosf) 50 mg; | D00775 |
[14] GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
[20] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway |
[7] 2, 3, 5, 8, 13, 17, 206 |
23 | Rivastigmine | [5] Exelon patch (rivastigmine transdermal system); Rivastigmine; Rivastigmine capsule; Rivastigmine patch 9.5 cm2; Rivastigmine transdermal patch; | D02558 D03822 |
[1] ACHE |
[2] Cholinergic synapse, Glycerophospholipid metabolism |
[3] 5, 6, 13 |
24 | Salsalate | [1] Salsalate; | D00428 |
[2] PTGS1, PTGS2 |
[21] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
[1] 5 |
25 | Suvorexant | [1] Suvorexant; | D10082 |
[2] HCRTR1, HCRTR2 |
[1] Neuroactive ligand-receptor interaction |
[3] 5, 6, 13 |
26 | Tideglusib | [1] Tideglusib; | - |
- |
- |
[2] 5, 113 |
27 | Trihexyphenidyl | [2] Primary cervical dystonia (trihexyphenidyl); Trihexyphenidyl; | D00787 D08638 |
[5] CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
[11] Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
[2] 5, 6 |
28 | Ubidecarenone | - | D01065 |
- |
- |
[12] 2, 5, 6, 8, 10, 46, 57, 86, 113, 193, 214, 215 |
29 | Valproic Acid | [3] Valproic acid; Valproic acid (vpa); Valproic acid and levocarnitine; | D00399 |
[7] ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
[17] Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
30 | Water | [13] 15 o water; 15-o labeled water; 5% glucose water solution; Dextrose, 5% in water; High water intake; Lactose in water; Pl 12185/0002 & pl 12185/0005(water for injection); Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; Water; Water for injection; Water for injections; Water for injections, ep; | D00001 |
- |
- |
[22] 2, 5, 6, 13, 17, 19, 28, 35, 46, 53, 57, 63, 65, 67, 78, 84, 97, 193, 226, 271, 278, 299 |
31 | Zolpidem | [4] Zolpidem; Zolpidem first dose; Zolpidem second dose; Zolpidem tartrate; | D00706 D08690 |
[16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
[7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
[2] 5, 6 |